Pulse Biosciences Announces Director, Officer Changes

TL;DR

Pulse Biosciences shakes up leadership with new directors and officers appointed.

AI Summary

Pulse Biosciences, Inc. announced on January 9, 2025, a series of significant corporate actions. These include the election of new directors, the appointment of key officers, and the establishment of new compensatory arrangements. The company also disclosed information related to Regulation FD and filed financial statements and exhibits.

Why It Matters

Changes in board and executive leadership can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• January 9, 2025 (date) — Date of Earliest Event Reported

FAQ

Key Financial Figures

• $0.001 — ange on Which Registered Common stock, $0.001 par value per share PLSE The Nasdaq
• $725,000 — ment. His current annual base salary is $725,000 and he is eligible for an annual target
• $18.43 — common stock, with an exercise price of $18.43 per share, the closing price of the Com
• $3.0B — ization of not less than three billion ($3.0B) for 270 consecutive calendar days and
• $48 million — the Company has generated not less than $48 million of GAAP product revenue over twelve mon
• $4.0B — lization of not less than four billion ($4.0B) for 270 consecutive calendar days and
• $115 million — the Company has generated not less than $115 million of GAAP product revenue over twelve mon
• $5.0B — lization of not less than five billion ($5.0B) for 270 consecutive calendar days and
• $175 million — the Company has generated not less than $175 million of GAAP product revenue over twelve mon
• $6.0B — alization of not less than six billion ($6.0B) for 270 consecutive calendar days and
• $300 million — the Company has generated not less than $300 million of GAAP product revenue over twelve mon
• $9.0B — lization of not less than nine billion ($9.0B) for 270 consecutive calendar days and
• $500 million — the Company has generated not less than $500 million of GAAP product revenue over twelve mon

Filing Documents

• plse20250109_8k.htm (8-K) — 37KB
• ex_764902.htm (EX-10.1) — 66KB
• ex_763693.htm (EX-99.1) — 12KB
• 0001437749-25-001006.txt ( ) — 269KB
• plse-20250109.xsd (EX-101.SCH) — 3KB
• plse-20250109_def.xml (EX-101.DEF) — 11KB
• plse-20250109_lab.xml (EX-101.LAB) — 15KB
• plse-20250109_pre.xml (EX-101.PRE) — 11KB
• plse20250109_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Appointment The Board of Directors of Pulse Biosciences, Inc. (the "Company") has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025 (the "Start Date"). In connection with his appointment, Mr. LaViolette will also serve as the Company's principal executive officer and principal financial officer. Mr. LaViolette has significant experience as a large-scale operator at global healthcare corporations as well as a leader to a diverse group of innovative medical technology startups as a venture investor and board member. As a Managing Partner at SV Health Investors, Mr. LaViolette invested in numerous portfolio companies and remains active on the Board of Directors of certain SV Health Investors portfolio companies. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. Prior to Boston Scientific, he also served as President, Cardiology, for CR Bard and various marketing roles at Kendall (Medtronic). Mr. LaViolette is currently a director of Edwards Lifesciences and Chairman of the Innovation Advisory Board at Mass General Brigham. Mr. LaViolette received his bachelor's degree in psychology from Fairfield University and his Master of Business Administration from Boston College. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. LaViolette. Mr. LaViolette was not selected to serve as the Company's Chief Executive Officer pursuant to any arrangement or understanding with any p

01

Item 7.01 Regulation FD Disclosure. On January 10, 2025, the Company issued a press release announcing the appointment of Mr. LaViolette as Chief Executive Officer and President. A copy of the Company's press release is attached as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Employment Agreement 99.1 Press Release of Pulse Biosciences, Inc. dated January 10, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: January 13, 2025 By: /s/ Paul A. LaViolette Paul A. LaViolette Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR